<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="533">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 24, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323800</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00245634</org_study_id>
    <nct_id>NCT04323800</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19</brief_title>
  <acronym>CSSC-001</acronym>
  <official_title>Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control
      (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day
      28.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of composite outcome of disease severity</measure>
    <time_frame>Day 28</time_frame>
    <description>The cumulative incidence of composite outcome of disease severity will be used in assessing the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19. This will be determined with the presence or occurrence of at least one of the following:
Death
Requiring mechanical ventilation and/or in ICU
non-ICU hospitalization, requiring supplemental oxygen;
non-ICU hospitalization, not requiring supplemental oxygen;
Not hospitalized, but with clinical and laboratory evidence of COVID-19 infection
Not hospitalized, no clinical evidence of COVID-19 infection, but with positive PCR for SARS-CoV-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-CoV-2 titers</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 0 (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-CoV-2 titers</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-CoV-2 titers</measure>
    <time_frame>Day 3</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-CoV-2 titers</measure>
    <time_frame>Day 7</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-CoV-2 titers</measure>
    <time_frame>Day 14</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-CoV-2 titers</measure>
    <time_frame>Day 90</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of SARS-CoV-2 PCR positivity</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Compare the rates of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SARS-CoV-2 PCR positivity</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Compare the duration (days) of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak quantity levels of SARS-CoV-2 RNA</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Compare the peak quantity levels of SARS-CoV-2 RNA amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of disease severity</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Cumulative incidence of disease severity between the anti-SARS-CoV-2 convalescent plasma and control groups after individuals develop SARS-CoV-2 infection. Severity of disease will be measured using a clinical event scale of disease severity (evaluated up to Day 28):
Death
Requiring mechanical ventilation and/or in ICU
non-ICU hospitalization, requiring supplemental oxygen;
non-ICU hospitalization, not requiring supplemental oxygen;
Not hospitalized, but with clinical and laboratory evidence of COVID-19 infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Coronavirus</condition>
  <condition>Convalescence</condition>
  <arm_group>
    <arm_group_label>High titer anti-SARS-CoV-2 plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with High titer anti-SARS-CoV-2 plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 non-immune plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with SARS-CoV-2 non-immune plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti- SARS-CoV-2 Plasma</intervention_name>
    <description>SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and was found to have a titer of neutralizing antibody &gt;1:64)</description>
    <arm_group_label>High titer anti-SARS-CoV-2 plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 non-immune Plasma</intervention_name>
    <description>Standard plasma collected prior to December 2019</description>
    <arm_group_label>SARS-CoV-2 non-immune plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18 years of age or older

          -  Close contact* exposure to person with COVID-19 within 96 hours of enrollment (and 120
             hours of receipt of plasma)

        High risk exposure as defined by CDC: Living in the same household as, being an intimate
        partner of, or providing care in a nonhealthcare setting (such as a home) for a person with
        symptomatic laboratory-confirmed COVID-19 infection without using recommended precautions
        for home care and home isolation

        AND

        Higher risk for severe illness as defined by CDC (any of the following):

          -  65 years of age

               -  Residence in a nursing home or long-term care facility 3.3 -Chronic lung disease
                  or moderate to severe asthma 3.4 -Heart disease 3.5 -Immunocompromising condition
                  including cancer treatment

               -  Severe obesity (body mass index [BMI] &gt;40)

               -  Uncontrolled diabetes

               -  Renal failure

               -  Liver disease

        Exclusion Criteria:

          -  Receipt any blood product in past 120 days

          -  Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion
             of the principal investigator, would affect subject safety and/or compliance

          -  Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of
             breath) at time of screening

          -  Nucleic acid testing evidence of COVID-19 infection at time of screening

          -  History of prior reactions to transfusion blood products

          -  Inability to complete therapy with the study product within 24 hours after enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shmuel Shoham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shmuel Shoham, MD</last_name>
    <phone>410-614-6702</phone>
    <email>TOID_CRC@jhmi.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Convalescence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing is governed by Johns Hopkins University Institutional Guidelines</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

